A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
Completed · Phase 1
Conditions studied: Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
In brief
The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or NUP98r.
Key facts
- Study ID
- NCT05326516
- Run by
- Syndax Pharmaceuticals
- People needed
- 30
- Starts
- 2022-03-09
- Expected to finish
- 2024-07-29
- Last updated by the study team
- 2024-08-13
Who can join
Age: 0 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, San Francisco (UCSF) Benioff Children's Hospital — San Francisco, California, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Children's Mercy Hospital — Kansas City, Missouri, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
- The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- St. Jude Children's Research Hospital, Inc — Memphis, Tennessee, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Texas Children's Cancer and Hematology Center — Houston, Texas, United States
- Jewish General Hospital — Québec, Montreal, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.